V

Vanda Pharmaceuticals
D

VNDA

5.10500
USD
0.18
(3.55%)
مغلق
حجم التداول
12,482
الربح لكل سهم
-0
العائد الربحي
-
P/E
-18
حجم السوق
297,663,075
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    A
    ALKS
    -0.150
    (-0.53%)
    28.200 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    J
    JAZZ
    -2.620
    (-2.11%)
    121.660 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    المزيد
الأخبار

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.